New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2009/01/01 by E.A. Eisenhauer, P. Therasse, J. Bogaerts +13 · 27 citations

paper · doi:10.1016/j.ejca.2008.10.026

Cited by

• Lite ENSAM: a lightweight cancer segmentation model for 3D Computed Tomography
• Phase I clinical trial of a recombinant oncolytic virus injection combined with PD-1 antibody-based gene therapy for recurrent head and neck cancer in China: An open-label study
• Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma
• Physical activity and systemic treatment outcomes in advanced thyroid cancer
• Scaling Artificial Intelligence for Multi-Tumor Early Detection with More Reports, Fewer Masks
• Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
• Agentic Systems in Radiology: Design, Applications, Evaluation, and Challenges
• Detection of Gene Fusions in Soft Tissue Sarcoma Using Next-Generation Sequencing
• A preserved TGFβ cytostatic response through DLD-mediated metabolic modulation undermines anti-TGFβ therapy in gastric cancer
• Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab
• Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases
• Compartmentalised Agentic Reasoning for Clinical NLI
• Leveraging Support Vector Regression, Radiomics and Dosiomics for Outcome Prediction in Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy (PULSAR)
• One-stage versus two-stage surgery for initially unresectable colorectal cancer liver metastases: post hoc analysis of the CAIRO5 trial
• NExON-Bayes: A Bayesian approach to network estimation informed by ordinal covariates
• Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer
• A stochastic agent-based model for simulating tumor-immune dynamics and evaluating therapeutic strategies
• Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study
• Clinical presentation and outcomes of medullary thyroid cancer in two European countries: impact of diagnostic strategies
• Patient-derived medullary thyroid cancer organoids: a potential model for mechanistic studies on diagnostics and therapy
• Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
• Unstable Prompts, Unreliable Segmentations: A Challenge for Longitudinal Lesion Analysis
• Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters
• Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer
• Cost-effectiveness analysis of capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy
• Learning from Anatomy: Supervised Anatomical Pretraining (SAP) for Improved Metastatic Bone Disease Segmentation in Whole-Body MRI
• Integrating tumor burden with survival outcome for treatment effect evaluation in oncology trials